Thursday, 13 September 2012
Intravenous posaconazole passes key test in patients
Whilst oral posaconazole has been licensed since 2006, development of an intravenous formulation has been challenging and slow.
Merck supported this study and will now advance IV posaconazole into randomised clinical studies. This complements a parallel development of an oral tablet of posaconazole. Since posaconazole is the most broad spectrum antifungal available, limited primarily by poor bioavailablity in highly susceptible patients and occasional resistance, these formulation improvements will help to deliver improved therapy for many patients.